MediWound's EscharEx Shows Safe, Effective, Rapid Debridement Of Leg Ulcers

MediWound Ltd MDWD announced results from its Phase 2 pharmacology study of EscharEx for the debridement of lower leg ulcers.
70% of patients achieved complete debridement during treatment within up to 8 applications. On average, complete debridement was achieved after 3.9 applications of EscharEx.
Additionally, an average reduction of 35% in wound size was achieved by the end of the 2-week follow-up period.
Related: MediWound Posts Promising EscharEx Data For Chronic Wounds.
In all patients that were positive for biofilm at baseline, the biofilm was reduced substantially to single individual microorganisms or entirely removed by the end of treatment.
Seven patients had positive red fluorescence (indicative of bacteria) at baseline, and the average red fluorescence was reduced from 1.69 cm2 pre-treatment to 0.60 cm2 post-treatment.
Biomarker analysis from wound fluid is ongoing, and safety data shows EscharEx is safe and well-tolerated.
Price Action: MDWD shares are up 1.10% at $1.83 during the premarket session on the last check Thursday.

Momentum85.91

GrowthNot Available

QualityNot Available

Value45.00

Short

Medium

Long